Clinical Trial

Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)

Study acronym: EVER-RECODE
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a prospective, open-label, multicenter, single-arm Phase Ib/II study evaluating the safety and preliminary efficacy of everolimus in patients with CDK12-deficient refractory metastatic colorectal cancer.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07435584
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Colorectal Cancer
Enrollment 38 participants
Start Date 2026-03-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-27